Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424398 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
A Phase 2 study of Conjunctivitis, Allergic, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 1
- Study location
NCT00424398 is a Phase 2 study of Conjunctivitis, Allergic that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 107 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00424398, a Phase 2 study of Conjunctivitis, Allergic, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bepreve
- DRUG Bepotastine Besilate
Study Locations (1)
California
- ISTA Pharmaceuticals, Inc. - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00424398
The ClinicalTrials.gov registry entry for NCT00424398 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Conjunctivitis, Allergic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00424398 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00424398 about?
NCT00424398 is a clinical study titled "Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis". The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
What is the current status of trial NCT00424398?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2007-02.
What conditions does trial NCT00424398 study?
This clinical trial studies the following conditions: Conjunctivitis, Allergic.
What interventions are being tested in trial NCT00424398?
The interventions under investigation include: Placebo (DRUG), Bepreve (DRUG), Bepotastine Besilate (DRUG).
Who is sponsoring clinical trial NCT00424398?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00424398 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.